Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial

Area of Science:

• Pediatric infectious diseases
• Clinical pharmacology
• Evidence-based medicine

Background:

• Community-acquired pneumonia (CAP) is a frequent childhood illness, necessitating evidence-based treatment guidelines.
• Optimizing antibiotic duration is crucial for effective treatment and antimicrobial stewardship.

Purpose of the Study:

• To compare the clinical cure rates of 5-day versus 10-day high-dose amoxicillin regimens for pediatric CAP.
• To evaluate the noninferiority of a shorter antibiotic course in children with uncomplicated CAP.

Main Methods:

• A 2-center, blinded, noninferiority randomized clinical trial (SAFER study) involving 281 children aged 6 months to 10 years.
• Participants received either 5 days of high-dose amoxicillin followed by placebo, or 10 days of high-dose amoxicillin.
• Clinical cure was assessed 14 to 21 days post-treatment.

Main Results:

• Per-protocol analysis showed clinical cure rates of 88.6% for the 5-day group and 90.8% for the 10-day group.
• Intention-to-treat analysis revealed clinical cure rates of 85.7% for the 5-day group and 84.1% for the 10-day group.
• The 5-day regimen was noninferior to the 10-day regimen for clinical cure.

Conclusions:

• Short-course (5-day) amoxicillin therapy is comparable to standard 10-day treatment for pediatric CAP in previously healthy children.
• Clinical guidelines should consider shorter amoxicillin courses for pediatric pneumonia to align with antimicrobial stewardship.
• This approach can help reduce antibiotic exposure and promote responsible antibiotic use in children.